Secondary glomerulonephritis in neurofibromatosis type 1. Two case reports
DOI:
https://doi.org/10.23938/ASSN.0720Keywords:
Neurofibromatosis type 1. Minimal change disease. Secondary amiloidosis. Nephrotic syndrome.Abstract
Neurofibromatosis type 1 (NF-1) is an autosomal dominant neurocutaneous disorder with systemic clinical manifestations. There are few publications about the renal effects of this disease, with renal vascular disease and adrenal tumors being the most frequent forms of renal involvement, while cases describing glomerular effects are exceptional.
Despite the lack of published information, common molecular mechanisms in both NF-1 and nephrotic syndrome, involving the mTOR pathway, were suggested to explain a possible association between both pathologies.
We present two cases of renal involvement in the form of nephrotic syndrome in patients diagnosed with NF1. A 41-year-old female was diagnosed of NF-1 in the context of a nephrotic syndrome with resistance to steroid treatment; the renal biopsy revealed a diagnosis of minimal changes disease. The second case is other 71-year-old woman with a history of NF-1, who presented a nephrotic syndrome and secondary renal amyloidosis.
Downloads
References
JETT K, FRIEDMAN JM. Clinical and genetic aspects of Neurofibromatosis. Genet Med 2010; 12: 1-11. https://doi.org/10.1097/GIM.0b013e3181bf15e3
UEDA K, AWAZU M, KONISHI Y. Persistent hypertension despite successful dilation of a stenotic renal artery in a boy with neurofibromatosis type 1. Am J Med Genet A 2013; 161A: 1154-1157. https://doi.org/10.1002/ajmg.a.35829
DUAN L, FENG K, TONG A. Renal artery stenosis due to neurofibromatosis type 1: case report and literature review. Eur J Med Res 2014; 19: 1. https://doi.org/10.1186/2047-783X-19-17.
FRANZ DN, WEISS BD. Molecular therapies for tuberous sclerosis and neurofibromatosis. Curr Neurol Neurosci Rep 2012; 12: 294-301. https://doi.org/10.1007/s11910-012-0269-4
SHIBATA T, KUDOH K, ISHII T. A case of membranous nephropathy associated with von Recklinghausen’s disease. Kidney Dial 1990; 29: 145-148.
DE CARIDI G, MASSARA M, SPINELLI F. Uncommon case of symptomatic left renal vein compression caused by neurofibroma. Asian Cardiovasc Thorac Ann 2016; 24: 492. https://doi.org/10.1177/0218492315573675
GUI X, ZHENG Y. Renal artery aneurysm at the hilum secondary to neurofibromatosis type I. Eur J Vasc Endovasc Surg 2015; 49: 464. https://doi.org/10.1016/j.ejvs.2015.01.022
GERSCH, M. S, TALOR, Z. Focal segmental glomerular sclerosis in a patient with neurofibromatosis type I. Am J Kidney Dis 2006; 47: 17-19. https://doi.org/10.1053/j.ajkd.2005.09.017
TOTH T, TRINN C, SIMON L, NAGY J. A case of membranous glomerulonephritis associated with Recklinghausen’s neurofibromatosis. Clin Nephrol 1996; 4: 271-272 .
KOKUBO T, HIKI Y, HORII A, KOBAYASHI Y. RECKLINGHAUSEN’S neurofibromatosis associated with membranous nephropathy. Nephron 1993; 6: 486. https://doi.org/10.1159/000187543
TANIGUCHI Y, YORIOKA N, KANBE M, OKUSHIN S, ODA H, NISHIDA Y et al. Parent and child cases of IgA nephropathy associated with von Recklinghausen’s disease. Nephron 1997; 75: 113-114. https://doi.org/10.1159/000189515
HYUN JI, MIN JW, LEE HM. Minimal changes nephrotic syndrome showing complete remission after resection of a neurofibroma in a type I neurofibromatosis patient. Korean J Intern Med 2017; 32: 186-189. https://doi.org/10.3904/kjim.2015.016
VIVARELLI M, MASELLA L, RUGGIERO B. Minimal Change Disease. Clin J Am Soc Nephrol 2017; 12: 332-345.
GLASSOCK RJ. Secondary minimal changes disease. Nephrol Dial Transplant 2003; 18: 52-58.
DOGAN A. Classification of amyloidosis by mass spectometry-based proteomics. En: Amyloid and related disorders. Surgical Pathology and clinical correlations. Pickens MM , Dogan A; Herrera GA. Cham: Humana Press, 2012: 261-272. https://doi.org/10.1007/978-1-60761-389-3_21
HSUEH YP, ROBERTS AM, VOLTA M. Bipartite Interaction between neurofibromatosis type I protein (neurofibromin) and syndecan transmembrane heparan sulfate proteoglycans. J Neurosci 2001; 21: 3764–3770. https://doi.org/10.1523/jneurosci.21-11-03764.2001
DE SCHEPPER S, BOUCNEAU J, WESTBROEK W, MOMMAAS M, ONDERWATER J, MESSIAEN L et al. Neurofibromatosis type 1 protein and amyloid precursor protein interact in normal human melanocytes and colocalize with melanosomes. J Invest Dermatol 2006; 126: 653-659. https://doi.org/10.1038/sj.jid.5700087
ABRAMOWICZ A, GOS M. Neurofibromin in neurofibromatosis type 1- mutations in NF1 genes as a cause of disease. Dev Period Med 2014; 18: 297-306.
AFSHINNIA F, VEGA-WARNER V, KILLEN P. Focal segmental glomerulosclerosis in association with neurofibromatosis type 1: a case report and proposed molecular pathways. Clin Kidney J 6, 2013: 208-210. https://doi.org/10.1093/ckj/sft010
GODEL M, HARTLEBEN B, HERBACH N, LIU S, ZSCHIEDRICH S, LU S et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011; 121: 2197-2209. https://doi.org/10.1172/jci44774
ITO N. mTOR activation triggers the unfolded protein response in pododyctes and leads to nephrotic syndrome. Lab Invest 2011; 91: 1584-1595. https://doi.org/10.1038/labinvest.2011.135
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
